City of Hope provides cancer support services to Amazon employees

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

City of Hope announced a partnership to provide a range of enhanced cancer support services to Amazon employees in the U.S.—including a dedicated phone line staffed by oncology nurses, specialized support for complex cancers and diagnosis and treatment plan review.

Amazon employs more than 275,000 people across the U.S.

The services include:

  • Cancer Support Line
    Whether an employee has a question about the side effects of treatment or needs emotional support, a dedicated team of cancer care nurses is available to answer questions and provide information. Employees can call about their own diagnosis or if a family member is diagnosed with cancer.

  • Expert Review
    Employees can benefit from this subspecialized expertise in their own communities by requesting that a City of Hope physician review their diagnosis and treatment plan and provide a written recommendation to the patient’s treating physician regarding the clinical appropriateness of the proposed therapeutic approach. If appropriate, City of Hope physicians will recommend improvements to the proposed treatment plan, including recommendations for–and interpretation of–genetic/genomic testing, identification of potential clinical trials and therapeutic options. An employee may also choose to go to City of Hope for an in-person evaluation with its premier physicians.

  • City of Hope Accountable Precision Oncology Program
    City of Hope specialists work with Amazon’s health plans to support the care of patients with the most complex cancers. City of Hope cancer experts directly engage local primary oncologists to provide a recommendation for appropriate genetic testing and accurate interpretation of test results and advice for optimal treatment, including the appropriate use of the most leading edge, targeted therapies.

Table of Contents

YOU MAY BE INTERESTED IN

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

Login